Lumos Pharma Inc. (LUMO)

Name: Lumos Pharma Inc. (LUMO) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Lumos Pharma Inc. (LUMO)

Stock Card

$4.34

$0.00 (0.00%)

As on 13-Dec-2024 09:30EDT

Market cap

$38 Mln

Revenue (TTM)

$2 Mln

P/E Ratio

P/B Ratio

7.6

Div. Yield

0 %

Lumos Pharma (LUMO) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 4.34 High: 4.34

52 Week Range

Low: -- High: --

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-1.7 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

0.4
Debt to Equity

0
Book Value

$--
EPS

$-4.3
Face value

--
Shares outstanding

8,648,620

10 Years Aggregate

CFO

$-207.76 Mln

EBITDA

$-302.35 Mln

Net Profit

$-292.40 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Lumos Pharma (LUMO)	36.5	-0.5	16.4	51.7	-17.6	-21.4	-35.0
BSE Sensex^*	-9.1	-1.5	2.9	-3.6	5.9	6.0	10.5
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 13-Dec-2024 | *As on 01-Sep-2026 | #As on 26-Oct-2023

Company	2023	2022	2021	2020	2019	2018	2017
Lumos Pharma (LUMO)	-11.9	-47.9	-80.6	56.8	66.4	-81.1	-21.1
S&P Small-Cap 600	13.9	-17.4	25.3	9.6	20.9	-9.7	11.7
BSE Sensex	18.7	4.4	22.0	15.8	14.4	5.9	27.9

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Peers

View Details

Company	Price ($)	Market Cap ($ Mln)	Revenue (TTM)	Net Profit (TTM)	OPM (%)	ROE (%)	P/E	P/B
Lumos Pharma (LUMO)	4.3	37.5	2.2	-34.9	-1,302.3	-312.4	--	7.6
Longboard Pharmaceuticals (LBPH)	60.0	2,342.0	0.0	-76.3	-1,093,125.0	-25.9	--	8.5
Pieris Pharmaceuticals (PIRS)	13.3	21.1	1.4	-16.0	-1,156.1	-83.5	--	1.1

Shareholding Pattern

View Details

About Lumos Pharma (LUMO)

Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of products and therapies for people with rare diseases. Its primary product candidate is LUM-201, an oral... growth hormone secretagogue ibutamoren, which is in Phase III clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders. The company has a clinical collaboration with Massachusetts General Hospital to evaluate oral LUM-201 in nonalcoholic fatty liver disease. Lumos Pharma, Inc. is headquartered in Austin, Texas. As of December 12, 2024, Lumos Pharma, Inc. was taken private. Read more

Founder, CEO & Chairman

Mr. Richard J. Hawkins
Founder, CEO & Chairman

Mr. Richard J. Hawkins
Headquarters

Austin, TX
Website

https://lumos-pharma.com

FAQs for Lumos Pharma (LUMO)

What is the current share price of Lumos Pharma Inc (LUMO) Today?

The share price of Lumos Pharma Inc (LUMO) is $4.34 (NASDAQ) as of 13-Dec-2024 09:30 EDT. Lumos Pharma Inc (LUMO) has given a return of -17.65% in the last 3 years.

What is the current PB & PE ratio of Lumos Pharma Inc (LUMO)?

Since, TTM earnings of Lumos Pharma Inc (LUMO) is negative, P/E ratio is not available.
The P/B ratio of Lumos Pharma Inc (LUMO) is 7.64 times as on 13-Dec-2024, a 47 premium to its peers’ median range of 5.18 times.

PE & PB ratio at the end of financial year.

Year	P/E Ratio	P/B Ratio
2023	-0.76	0.94
2022	-0.96	0.50
2021	-1.90	0.65
2020	-52.29	2.54
2019	-0.24	0.13

What is the 52 Week High and Low of Lumos Pharma Inc (LUMO)?

The 52-week high and low of Lumos Pharma Inc (LUMO) are Rs -- and Rs -- as of 02-Sep-2026.

What is the market cap of Lumos Pharma Inc (LUMO)?

Lumos Pharma Inc (LUMO) has a market capitalisation of $ 38 Mln as on 13-Dec-2024. As per SEBI classification, it is a Small Cap company.

Should I invest in Lumos Pharma Inc (LUMO)?

Before investing in Lumos Pharma Inc (LUMO), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.

Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.